A recent open-label trial published in the Indian Journal of Psychological Medicine in October 2024 demonstrates that a culturally adapted social cognitive intervention significantly enhances facial emotion recognition and daily functioning in patients with schizophrenia. Remarkably, these therapeutic gains produced a strong effect size (partial eta squared = 0.47) that remained fully sustained at three-month follow-up.

Although facial emotion recognition (FER) deficits represent core features driving socio-occupational dysfunction in schizophrenia, standard non-pharmacological therapies explain only 20% to 40% of functional variance, creating a therapeutic gap in non-Western settings. Addressing this, Umesh Thonse, Samir Kumar Praharaj, and Podila Sathya Venkata Narasimha Sharma from Kasturba Medical College Manipal, Rishikesh V. Behere from KEM Hospital and Research Center Pune, and Nicole Frommann from Heinrich Heine University Dusseldorf evaluated the efficacy of the Training of Affect Recognition—Indian Version (TAR-IV) against treatment as usual (TAU).

Therefore, the open-label trial evaluated 88 adults with stable schizophrenia, comparing 12 sessions of TAR-IV add-on therapy (n=45) to treatment as usual (n=43) over 4 to 6 weeks. Excluding patients with comorbid psychiatric or neurological conditions, emotion recognition and socio-occupational functioning were assessed at baseline, post-treatment, and follow-up while controlling for baseline psychopathology.

Key Clinical Findings of the Study Includes:

  • Enhanced Emotion Accuracy: Investigators demonstrated that the TAR-IV group achieved significantly higher post-intervention TRENDS Accuracy Score (TRACS) total scores (37.63 ± 6.40) than TAU controls (28.93 ± 5.17; p = .001, partial eta squared = 0.47), maintaining superiority at follow-up (37.13 ± 6.65 vs. 28.72 ± 4.96).
  • Threat Recognition Improvement: Researchers observed marked gains in identifying basic emotions—particularly threat-related fear and disgust alongside anger, surprise, and happiness (p = .001)—with a significant reduction in under-identification errors (Z = 4.10, p = .001).
  • Socio-Occupational Gains: Authors reported significant baseline-to-post-intervention improvements in total SOFS impairment scores within the TAR-IV group (21.38 to 19.22 at post-assessment and 18.63 at follow-up vs. 18.00 to 17.10 and 17.34 in TAU; p = .008), although significance attenuated after covarying for baseline psychopathology (p = .13).
  • Predictors of Response: Trial regression analysis revealed that lower age of onset (β = -0.22, p = .01) and poorer baseline working memory performance on Verbal N-Back Test one-back hits (β = -1.24, p = .02) significantly predicted greater emotion recognition gains, explaining 21.45% of variance.
  • Intensity and Durability: Study findings confirmed robust therapeutic efficacy across both low-intensity (t = 6.57, p = .001) and high-intensity (t = 8.30, p = .001) expressions, with treatment effects fully sustained over 2 to 3 months.

The results suggest that TAR-IV is an effective culturally adapted social cognitive intervention that produces durable improvements in facial emotion recognition accuracy (TRACS score improving to 37.63, p = .001) and socio-occupational functioning in schizophrenia. Furthermore, these findings validate the cross-cultural applicability of emotion training modules in non-Western patient populations.

Integrating culturally adapted affect recognition modules like TAR-IV into routine rehabilitation programs may provide clinicians with a targeted intervention to remediate social cognitive deficits in schizophrenia.

Although the study was limited by an open-label, non-randomized design and a regional South Indian sample, future multi-center randomized controlled trials across diverse demographics are warranted to confirm generalizability.

Reference
Thonse U, Behere RV, Frommann N, Praharaj SK, Sharma PSVN. Efficacy of a Culturally Adapted Emotion Recognition Training Program in Improving Facial Emotion Recognition in Persons with Schizophrenia. Indian J Psychol Med. 2026;48(6):575–583.



Tags:    
Article Source : Indian Journal of Psychological Medicine

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .